Jacobs Levy Equity Management’s Xeris Biopharma Holdings XERS Stock Holding History

Jacobs Levy Equity Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-181,877	Closed	-$849K	–	1134
2025 Q2	$849K	Sell	181,877 -73,683	-29%	-$338K	﹤0.01%	785
2025 Q1	$1.4M	Buy	+255,560	New	+$1.03M	0.01%	742
2021 Q2	–	Sell	-162,321	Closed	-$732K	–	1129
2021 Q1	$732K	Buy	162,321 +25,924	+19%	+$140K	0.01%	799
2020 Q4	$671K	Buy	136,397 +100,946	+285%	+$505K	0.01%	811
2020 Q3	$210K	Sell	35,451 -17,992	-34%	-$71.9K	﹤0.01%	957
2020 Q2	$142K	Sell	53,443 -23,317	-30%	-$81.2K	﹤0.01%	989
2020 Q1	$150K	Buy	+76,760	New	+$330K	﹤0.01%	923

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Jacobs Levy Equity Management's XERS Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 181,877 shares — an estimated $849K sold.

Jacobs Levy Equity Management first reported a position in XERS in Q1 2020 and held it in 7 quarters. The position peaked at $1.4M in Q1 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

Jacobs Levy Equity Management reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 181,877 Xeris Biopharma Holdings shares in Q3 2025, an estimated $849K.
Jacobs Levy Equity Management first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 7 quarters.
Jacobs Levy Equity Management's Xeris Biopharma Holdings position peaked at $1.4M in Q1 2025.
230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.